Sign In
Buy SNY
$43.75
-0.230 (-0.523%)
At Close: Jul 21, 2026
Why GSK May Have Bet Too Big on a Pandemic Pipeline
11:57am, Saturday, 07'th May 2022 The Motley Fool
Its late-stage pipeline is heavily weighted toward pandemic treatments.
Tracking Ken Fisher's Fisher Asset Management Portfolio - Q1 2022 Update
05:44am, Saturday, 07'th May 2022 Seeking Alpha
Ken Fisher’s 13F portfolio value decreased from ~$179B to ~$165B in Q1 2022. Find more details here...
3 Top Biotech Stocks to Buy Right Now
02:45pm, Friday, 06'th May 2022 The Motley Fool
These three pharma stocks each pay market-beating dividends to shareholders.
3 Top Biotech Stocks to Buy Right Now
10:45am, Friday, 06'th May 2022
These three pharma stocks each pay market-beating dividends to shareholders.
EuroAPI gains on market debut after spin-off from Sanofi
06:56am, Friday, 06'th May 2022
Shares in EuroAPI, the drug ingredients business spun off from Sanofi, rose on their Paris stock market debut on Friday, defying a wider market decline.
Regeneron (REGN) Q1 Earnings Beat, COVID Antibody Sales Affected
03:54pm, Wednesday, 04'th May 2022 Zacks Investment Research
Regeneron (REGN) beats on Q1 earnings and sales record year-over-year growth on the solid performance of Dupixent and Eylea.
Why Kymera Therapeutics Stock Is Getting Hammered Today
05:09pm, Tuesday, 03'rd May 2022 The Motley Fool
The biotech upset investors today with disappointing news for its lead program.
Will Eylea, Dupixent Buoy Regeneron's (REGN) Q1 Earnings?
04:21pm, Monday, 02'nd May 2022 Zacks Investment Research
Regeneron's (REGN) first-quarter performance might have gotten a boost from the solid performance of Eylea and Dupixent.
Sanofi (SNY) Q1 2022 Earnings Call Transcript
08:30pm, Friday, 29'th Apr 2022 The Motley Fool
SNY earnings call for the period ending March 31, 2022.
Seagen's (SGEN) Q1 Earnings & Revenues Surpass Estimates
04:43pm, Friday, 29'th Apr 2022 Zacks Investment Research
Seagen (SGEN) reports narrower-than-expected loss in the first quarter of 2022 while its revenues beat estimates.
BioMarin (BMRN) Q1 Earnings and Revenues Beat Estimates
06:35pm, Thursday, 28'th Apr 2022 Zacks Investment Research
Biomarin Pharmaceutical's (BMRN) first-quarter earnings and sales beat estimates. BMRN also raises its financial guidance for 2022 Voxzogo sales by $10 million.
Sanofi (SNY) Q1 Earnings Top, Vaccines Recover, CHC Sales Rise
02:52pm, Thursday, 28'th Apr 2022 Zacks Investment Research
Sanofi (SNY) beats first-quarter estimates for earnings and sales. Dupixent drives sales growth along with strong recovery in travel vaccines. Consumer healthcare sales remain strong.
Sanofi SA (SNY) CEO Paul Hudson on Q1 2022 Results - Earnings Call Transcript
02:10pm, Thursday, 28'th Apr 2022
Sanofi SA (NASDAQ:SNY ) Q1 2022 Earnings Conference Call April 28, 2022 8:30 AM ET Company Participants Eva Schaefer-Jansen - Head, IR Paul Hudson - CEO & Director John Reed - EVP & Global Head, Resea
The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates
12:52pm, Thursday, 28'th Apr 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Moderna Seeks FDA Emergency Use Nod For COVID-19 Shot In Kids 2-6
Moderna Inc (NASDAQ: MRNA) submitt
Sanofi (SNY) Q1 Earnings Top, Vaccines Recover, CHC Sales Rise
12:02pm, Thursday, 28'th Apr 2022
Sanofi (SNY) beats first-quarter estimates for earnings and sales. Dupixent drives sales growth along with strong recovery in travel vaccines.
